Wcn26-5558 Efficacy and Safety of Hsk39297, a Once-Daily Oral CFB Inhibitor, in Patients With Primary Immunoglobulin a Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial | Synapse